Nuredis, a pre-clinical stage company, is developing small molecule therapies to treat a group of inherited neurodegenerative and neuromuscular diseases caused by the expansion of normally-short nucleotide repeats sequences in human genes, with Huntington's Disease as the first indication. Nuredis' investigational therapies target a regulatory mechanism involved in the transcription of expanded repeats. The technology is based on inhibiting the process that enables cells to make the toxic gene products that cause nucleotide repeat diseases. The closely-held company is exclusively funded by Alafi Capital Company, LLC. The therapeutic approach was invented by Nuredis co-founders Stanley N. Cohen, Professor of Genetics at Stanford University and Tzu-Hao Cheng, Professor of Molecular Biology at National Yang Ming University (NYMU) in Taiwan, and their colleagues.
| Website | http://www.nuredis.com |
| Revenue | $6 million |
| Employees | View employees |
| Address | 1455 Adams Dr Ste 1120, Menlo Park, California 94025, US |
| Phone | +1 650-326-1622 |
| Industry | Software General, Software |
| Competitors | Accenture, Wipro, Tata Consultancy Services, Infosys, Capgemini, Tech Mahindra, Persistent Systems, HCLTech, Cognizant Softvision, Syntelsoft Inc +44 more (view full list) |
| SIC | SIC Code 737 Companies, SIC Code 73 Companies |
| NAICS | NAICS Code 5112 Companies, NAICS Code 51 Companies, NAICS Code 511 Companies, NAICS Code 513 Companies |
Looking for a particular Nuredis employee's phone or email?
Nuredis Questions
The Nuredis annual revenue was $6 million in 2026.
Nuredis is based in Menlo Park, California.
The NAICS codes for Nuredis are [5112, 51, 511, 513].
The SIC codes for Nuredis are [737, 73].
